Neulasta® (pegfilgrastim) Start with support
Site Map | Contact Us | Privacy Statement | Terms of Use
Home For Healthcare Professionals
Search GO
 
  • About Low White
    Blood Cell Counts
    • Who is Most at Risk?
    • Understanding Your Blood Counts
  • How Neulasta®
    Can Help
  • Helping to Protect
    Against Infection
  • Questions to Ask
    Your Doctor
  • Support and
    Resources
    • Patient Assistance
    • ChemoCoach®
      Newsletters
    • Information on
      Neutropenia and
      Cancer
  • Glossary of Terms
  • Important Safety
    Information

Site Map

Home Page
 
 Professional  Patient
 
About Neutropenia
First Cycle Neutropenic Events
Chemotherapy Regimen Risk
Proactive Risk Assessment
Facts About Neutropenia
 
About Neulasta®
First Cycle Protection
Safety Information
Dosage and Administration
Frequently Asked Questions
Neulasta® Fact Sheet
 
Reimbursement Information
Reimbursement Connection®
 
Professional Resources
Medical Information Connection™
Links
 
Important Product Safety Information
 
Contact Us
 
Privacy Statement
 
Terms of Use
About Low White Blood Cell Counts
Who is Most at Risk?
Understanding Your Blood Counts
 
How Neulasta® Can Help
 
Helping to Protect Against Infection
 
Questions to Ask Your Doctor
 
Support and Resources
Patient Assistance
ChemoCoach® Newsletters
Information on Neutropenia and Cancer
   
Glossary of Terms
   
Important Safety Information


Neulasta® (pegfilgrastim) is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells.

Important safety information
Ruptured spleen (including fatal cases), a serious lung problem called acute respiratory distress syndrome, and serious allergic reactions have been reported. Call your doctor or seek emergency care right away if you have abdominal or shoulder tip pain, shortness of breath, trouble breathing, a fast rate of breathing, or any allergic reaction. The most common side effect of this injection is mild to moderate bone pain.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Amgen.com | Chemotherapy.com
Neulasta® Product Information

© 2010 Amgen. All rights reserved.